1 Explosive Cannabis Stock Primed for a Comeback in 2020

Marijuana stocks take a beating in the market, but Aphria Inc (TSX:APHA), (NYSE:APHA) still looks set to make a comeback in 2020.

Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

If you actively invest in cannabis stocks, you are probably concerned about the current slump in the market. Cannabis stocks have taken a beating in the markets this week.

Research reports about medical and health risks of vaping have unsettled investors, who now expect a decline in demand.

Tensions because of the U.S.-China trade relations have also had an impact. The blacklisting of eight more Chinese tech companies by the U.S. administration means the cannabis supply agreements could be the next to go.

China is a major supplier of cannabis and other related products in the U.S. market. Chinese companies own more than half of the cannabis-related patents around the world, and any bans on supply to the U.S. could affect the retailer stock prices adversely.

There are also the scandals such as CannTrust being caught with illegal marijuana — scandals that have broken investor trust. The good news is that with every market crash, there comes an opportunity to purchase stocks at a better price.

Aphria valuation and market sentiment

Aphria Inc’s (TSX:APHA)(TSX:APHA) has had a roller-coaster ride for 2019, with share prices skyrocketing then plummeting. The good news is that Aphria is one of the few cannabis supply companies that have consistently surpassed estimates about its earnings results for the year.

Its operational performance helped boost the overall analyst and investor confidence for the company.

The stock is currently trading around the price of $6.64 per share at writing, which is much lower than its 52-week high of $17.60 per share. The decline in Aphria’s share price and valuation could mostly reflect sector-wide concerns in the industry rather than the company’s performance.

Disappointing news

In other news, Aleafia also announced that it terminated its wholesale cannabis supply agreement with Aphria after the latter failed to meet its supply obligations.

Aphria shares have fallen by 5% at the announcement of the termination. Its management noted that the company had every intention of fulfilling the obligation, and they were disappointed at the decision by Aleafia.

Outlook for Aphria in 2020

Despite the seeming collapse of the supply deal with Aleafia, the outlook for Aphria stock growth remains positive for 2020. At its current share price, the stock is extremely undervalued and highly recommended by analysts as an attractive investment opportunity.

The Canadian company is focused on leveraging the Cannabis 2.0 opportunity in Canada and poised to take control of the edible Cannabis market.

2020 will be a year of growth for the business. Market experts have forecast that the company’s fiscal 2020 EBITDA will be more than 64 million dollars.

Foolish takeaway

The cannabis sector has shown a significant level of volatility these days. Faced with the uncertainty of cancelled supply agreements, failed mergers, and the escalating U.S.-China trade war, it’s necessary for you as an investor to keep a close eye on the developments in the market.

When you think that the marijuana market has reached the bottom, Aphria should be one of the first stocks you consider purchasing.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Adam Othman has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »